Effects of therapy with bendroflumethiazide in patients with recurrent renal calcium stones.
Forty-four patients with recurrent formation of calcium-containing renal stones were treated with bendroflumethiazide for at least 2 years. Prior to treatment each patient had formed, on average, one stone per year for 8 years; during treatment only 4 patients formed new stones. A reduction in urinary calcium excretion was seen in almost all patients irrespective of their initial urinary calcium level. The apparent clinical benefit was not related to pre-treatment urinary electrolyte levels. Side effects were slight: one patient developed symptomatic hyperuricaemia and in one case sustained hypercalcaemia was found. Long-term treatment with thiazides appears to be a safe and effective method for the prevention of recurrent calcium stones.
D001539:Bendroflumethiazide / Q000627:therapeutic use*; D002118:Calcium / Q000378:metabolism; D004573:Electrolytes / Q000097:blood / Q000652:urine; D006801:Humans; D007669:Kidney Calculi / Q000378:metabolism / Q000517:prevention & control* / Q000652:urine; D012008:Recurrence; D013997:Time Factors; D014527:Uric Acid / Q000378:metabolism
D004573:Electrolytes; D014527:Uric Acid; D001539:Bendroflumethiazide; D002118:Calcium